EUROPE DRUG DISCOVERY MARKET FORECAST 2017-2024
KEY FINDINGS
The Europe drug discovery market in 2016 was worth $9952 million. The market is expected to reach $19300 million by 2024 at a CAGR of 8.6% between 2016 and 2024. Aging population, rise in healthcare spending and increase in lifestyle oriented diseases and fatalities are some of the factors driving the drug discovery market in the Europe region.
MARKET INSIGHTS
The drug discovery market by technology is segmented into QPCR, DNA Microarrays, Protein Microarrays, High–throughput screening, mass spectrometer, GEL Electrophoresis, Chromatograph, Protein and Nucleic Acid Isolation and other technologies. The countries analyzed in the Europe drug discovery market are UK, France, Germany, Spain, Italy and rest of Europe. The entry of new companies in the market and substitute products poses a threat to the Europe drug discovery market.
Discovery of new drugs being delayed due to government regulations is a big restraint. Also, the drug market is shifting from branded to generics drugs which limit the growth of the drug discovery market in this region.
COMPETITIVE INSIGHTS
Major players in the Drug Discovery markets are Sanofi, Johnson And Johnson, AstraZeneca PLC, Bayer AG, BoehringerIngelheim, Pfizer, INC., Glaxosmithkline LLC, Eli Lily, Merck & Co. INC., Roche Holding AG. Sanofi, formerly Sanofi-Aventis,
The Europe drug discovery market in 2016 was worth $9952 million. The market is expected to reach $19300 million by 2024 at a CAGR of 8.6% between 2016 and 2024. Aging population, rise in healthcare spending and increase in lifestyle oriented diseases and fatalities are some of the factors driving the drug discovery market in the Europe region.
MARKET INSIGHTS
The drug discovery market by technology is segmented into QPCR, DNA Microarrays, Protein Microarrays, High–throughput screening, mass spectrometer, GEL Electrophoresis, Chromatograph, Protein and Nucleic Acid Isolation and other technologies. The countries analyzed in the Europe drug discovery market are UK, France, Germany, Spain, Italy and rest of Europe. The entry of new companies in the market and substitute products poses a threat to the Europe drug discovery market.
Discovery of new drugs being delayed due to government regulations is a big restraint. Also, the drug market is shifting from branded to generics drugs which limit the growth of the drug discovery market in this region.
COMPETITIVE INSIGHTS
Major players in the Drug Discovery markets are Sanofi, Johnson And Johnson, AstraZeneca PLC, Bayer AG, BoehringerIngelheim, Pfizer, INC., Glaxosmithkline LLC, Eli Lily, Merck & Co. INC., Roche Holding AG. Sanofi, formerly Sanofi-Aventis,
1. RESEARCH SCOPE
1.1. STUDY GOALS
1.2. SCOPE OF THE MARKET STUDY
1.3. WHO WILL FIND THIS REPORT USEFUL?
1.4. STUDY AND FORECASTING YEARS
2. RESEARCH METHODOLOGY
2.1. SOURCES OF DATASECONDARY DATA
2.1.1. PRIMARY DATA
2.2. TOP DOWN APPROACH
2.3. BOTTOM-UP APPROACH
2.4. DATA TRIANGULATION
3. EXECUTIVE SUMMARY
4. MARKET OVERVIEW
4.1. MARKET DRIVERS
4.1.1. AGING POPULATION
4.1.2. SPENDING ON HEALTHCARE HAS BEEN INCREASED
4.1.3. INCREASE IN LIFE STYLE ORIENTED DISEASES & FATALITIES
4.2. MARKET RESTRAINT
4.2.1. GOVERNMENT REGULATIONS DELAYING THE PROCESSES
4.2.2. POOR ACCESS TO THE HEALTHCARE SERVICES IN DEVELOPING MARKETS
4.2.3. MARKET IS SHIFTING FROM BRANDED TO GENERIC DRUGS
4.3. MARKET CHALLENGES
4.3.1. COST BARRIER FOR LOCAL PEOPLE IN EMERGING ECONOMIES
4.4. MARKET OPPORTUNITIES
4.4.1. EXTENSIVE R & D FOR NEW PRODUCT LAUNCHES
5. BY TECHNOLOGY
5.1. QPCR
5.2. DNA MICROARRAYS
5.3. PROTEIN MICROARRAYS
5.4. HIGH-THROUGHPUT SCREENING
5.5. MASS SPECTROMETER
5.6. GEL ELECTROPHORESIS
5.7. CHROMATOGRAPH
5.8. PROTEIN AND NUCLEIC ACID ISOLATION
5.9. OTHER TECHNOLOGIES
6. KEY ANALYTICS
6.1. PORTER’S FIVE FORCES ANALYSIS
6.1.1. THREATS OF NEW ENTRANTS
6.1.2. COMPETITIVE RIVALRY
6.1.3. BARGAINING POWER OF BUYERS
6.1.4. BARGAINING POWER OF SUPPLIERS
6.1.5. THREAT OF SUBSTITUTE PRODUCTS
6.2. VALUE CHAIN ANALYSIS
6.3. KEY EXCERPTS OF THE STUDY
6.3.1. RELAXATION IN THE REGULATIONS BY THE GOVERNMENT WHICH STOPS RESEARCHERS FROM DOING RESEARCH.
6.3.2. MARKET LEADERS SHOULD OPEN UP THEIR BRANCHES AND RESEARCH LABS IN EMERGING MARKETS.
6.4. PESTLE ANALYSIS
6.5. OPPORTUNITY MATRIX
6.6. VENDOR LANDSCAPE
7. BY REGION
7.1. EUROPE
7.1.1. UK
7.1.2. FRANCE
7.1.3. GERMANY
7.1.4. SPAIN
7.1.5. ITALY
7.1.6. REST OF EUROPE
8. COMPANY PROFILES
8.1. SANOFI
8.1.1. COMPANY OVERVIEW
8.1.2. PRODUCT PORTFOLIO
8.1.3. SWOT ANALYSIS
8.1.4. STRATEGIC ANALYSIS
8.2. JOHNSON AND JOHNSON
8.2.1. COMPANY OVERVIEW
8.2.2. PRODUCT PORTFOLIO
8.2.3. SWOT ANALYSIS
8.2.4. STRATEGIC ANALYSIS
8.3. ASTRAZENECA PLC
8.3.1. COMPANY OVERVIEW
8.3.2. PRODUCT PORTFOLIO
8.3.3. SWOT ANALYSIS
8.3.4. STRATEGIC ANALYSIS
8.4. BAYER A
8.4.1. COMPANY OVERVIEW
8.4.2. PRODUCT PORTFOLIO
8.4.3. SWOT ANALYSIS
8.4.4. STRATEGIC ANALYSIS
8.5. BOEHRINGER INGELHEIM
8.5.1. COMPANY OVERVIEW
8.5.2. PRODUCT PORTFOLIO
8.5.3. SWOT ANALYSIS
8.5.4. STRUCTURAL ANALYSIS
8.6. PFIZER, INC.
8.6.1. COMPANY OVERVIEW
8.6.2. SWOT ANALYSIS
8.6.3. STRATEGIC ANALYSIS
8.7. GLAXOSMITHKLINE LLC
8.7.1. COMPANY OVERVIEW
8.7.2. PRODUCT PORTFOLIO
8.7.3. SWOT ANALYSIS
8.7.4. STRATEGIC ANALYSIS
8.8. ELI LIL
8.8.1. COMPANY OVERVIEW
8.8.2. PRODUCT PORTFOLIO
8.8.3. SWOT ANALYSIS
8.8.4. STRATEGIC ANALYSIS
8.9. MERCK & CO. INC.
8.9.1. COMPANY OVERVIEW
8.9.2. PRODUCT PORTFOLIO
8.9.3. SWOT ANALYSIS
8.9.4. STRATEGIC ANALYSIS
8.10. ROCHE HOLDING AG
8.10.1. COMPANY OVERVIEW
8.10.2. PRODUCT PORTFOLIO
8.10.3. SWOT ANALYSIS
8.10.4. STRATEGIC ANALYSIS
TABLE LIST
TABLE 1 FACT SHEET OF EUROPE FATALITIES
TABLE 2 EUROPE QPCR MARKET, 2016-2024, (IN $MILLION)
TABLE 3 EUROPE DNA MICROARRAYS, 2016-2024, (IN $MILLION)
TABLE 4 EUROPE PROTEIN MICROARRAYS, 2016-2024(IN $MILLION)
TABLE 5 EUROPE HIGH THROUGHPUT SCREENING, 2016-2024(IN $MILLION)
TABLE 6 EUROPE MASS SPECTROMETRY, 2016-2024(IN $MILLION)
TABLE 7 EUROPE GEL ELECTROPHORESIS MARKET, 2016-2024, (IN $MILLION)
TABLE 8 EUROPE CHROMATOGRAPHY MARKET, 2016-2024 (IN $MILLION)
TABLE 9 EUROPE PROTEIN AND NUCLEIC ACID ISOLATION MARKET, 2016-2024 (IN $MILLION)
TABLE 10 EUROPE OTHER TECHNOLOGIES MARKET, 2016-2024 (IN $MILLION)
TABLE 11 EUROPE DRUG DISCOVERY MARKET, 2016-2024, (IN $MILLION)
TABLE 12 FATALITY IN EUROPE IN 2012
FIGURES LIST
FIGURE 1 EUROPE DRUG DISCOVERY MARKET, 2016-2024, (IN $MILLION)
FIGURE 2 EUROPE DRUG DISCOVERY MARKET SHARE, BY TECHNOLOGY, 2016 & 2024
FIGURE 3 EUROPE QPCR MARKET, 2016-2024 (IN $MILLION)
FIGURE 4 EUROPE DNA MICROARRAYS MARKET, 2016-2024 (IN $MILLION)
FIGURE 5 EUROPE PROTEIN MICROARRAYS MARKET, 2016-2024 (IN $MILLION)
FIGURE 6 EUROPE HIGH THROUGHPUT SCREENING MARKET, 2016-2024 (IN $MILLION)
FIGURE 7 EUROPE MASS SPECTROMETRY MARKET, 2016-2024 (IN $MILLION)
FIGURE 8 EUROPE GEL ELECTROPHORESIS MARKET, 2016-2024 (IN $MILLION)
FIGURE 9 EUROPE CHROMATOGRAPHY MARKET, 2016-2024 (IN $MILLION)
FIGURE 10 EUROPE PROTEIN AND NUCLEIC ACID ISOLATION MARKET, 2016-2024 (IN $MILLION)
FIGURE 11 EUROPE OTHER TECHNOLOGIES MARKET, 2016-2024 (IN $MILLION)
FIGURE 12 EUROPE DRUG DISCOVERY MARKET, 2016-2024, (IN $MILLION)
FIGURE 13 COUNTRY-WISE MARKET SHARE, 2016
FIGURE 14 UNITED KINGDOM DRUG DISCOVERY MARKET, 2016-2024, (IN $MILLION)
FIGURE 15 FRANCE DRUG DISCOVERY MARKET, 2016-2024, (IN $MILLION)
FIGURE 16 GERMAN DRUG DISCOVERY MARKET, 2016-2024 (IN $MILLION)
FIGURE 17 SPAIN DRUG DISCOVERY MARKET, 2016-2024, (IN $MILLION)
FIGURE 18 ITALY DRUG DISCOVERY MARKET, 2016-2024 (IN $MILLION)
FIGURE 19 REST OF EUROPE (ROE) DRUG DISCOVERY MARKET, 2016-2024 (IN $MILLION)
1.1. STUDY GOALS
1.2. SCOPE OF THE MARKET STUDY
1.3. WHO WILL FIND THIS REPORT USEFUL?
1.4. STUDY AND FORECASTING YEARS
2. RESEARCH METHODOLOGY
2.1. SOURCES OF DATASECONDARY DATA
2.1.1. PRIMARY DATA
2.2. TOP DOWN APPROACH
2.3. BOTTOM-UP APPROACH
2.4. DATA TRIANGULATION
3. EXECUTIVE SUMMARY
4. MARKET OVERVIEW
4.1. MARKET DRIVERS
4.1.1. AGING POPULATION
4.1.2. SPENDING ON HEALTHCARE HAS BEEN INCREASED
4.1.3. INCREASE IN LIFE STYLE ORIENTED DISEASES & FATALITIES
4.2. MARKET RESTRAINT
4.2.1. GOVERNMENT REGULATIONS DELAYING THE PROCESSES
4.2.2. POOR ACCESS TO THE HEALTHCARE SERVICES IN DEVELOPING MARKETS
4.2.3. MARKET IS SHIFTING FROM BRANDED TO GENERIC DRUGS
4.3. MARKET CHALLENGES
4.3.1. COST BARRIER FOR LOCAL PEOPLE IN EMERGING ECONOMIES
4.4. MARKET OPPORTUNITIES
4.4.1. EXTENSIVE R & D FOR NEW PRODUCT LAUNCHES
5. BY TECHNOLOGY
5.1. QPCR
5.2. DNA MICROARRAYS
5.3. PROTEIN MICROARRAYS
5.4. HIGH-THROUGHPUT SCREENING
5.5. MASS SPECTROMETER
5.6. GEL ELECTROPHORESIS
5.7. CHROMATOGRAPH
5.8. PROTEIN AND NUCLEIC ACID ISOLATION
5.9. OTHER TECHNOLOGIES
6. KEY ANALYTICS
6.1. PORTER’S FIVE FORCES ANALYSIS
6.1.1. THREATS OF NEW ENTRANTS
6.1.2. COMPETITIVE RIVALRY
6.1.3. BARGAINING POWER OF BUYERS
6.1.4. BARGAINING POWER OF SUPPLIERS
6.1.5. THREAT OF SUBSTITUTE PRODUCTS
6.2. VALUE CHAIN ANALYSIS
6.3. KEY EXCERPTS OF THE STUDY
6.3.1. RELAXATION IN THE REGULATIONS BY THE GOVERNMENT WHICH STOPS RESEARCHERS FROM DOING RESEARCH.
6.3.2. MARKET LEADERS SHOULD OPEN UP THEIR BRANCHES AND RESEARCH LABS IN EMERGING MARKETS.
6.4. PESTLE ANALYSIS
6.5. OPPORTUNITY MATRIX
6.6. VENDOR LANDSCAPE
7. BY REGION
7.1. EUROPE
7.1.1. UK
7.1.2. FRANCE
7.1.3. GERMANY
7.1.4. SPAIN
7.1.5. ITALY
7.1.6. REST OF EUROPE
8. COMPANY PROFILES
8.1. SANOFI
8.1.1. COMPANY OVERVIEW
8.1.2. PRODUCT PORTFOLIO
8.1.3. SWOT ANALYSIS
8.1.4. STRATEGIC ANALYSIS
8.2. JOHNSON AND JOHNSON
8.2.1. COMPANY OVERVIEW
8.2.2. PRODUCT PORTFOLIO
8.2.3. SWOT ANALYSIS
8.2.4. STRATEGIC ANALYSIS
8.3. ASTRAZENECA PLC
8.3.1. COMPANY OVERVIEW
8.3.2. PRODUCT PORTFOLIO
8.3.3. SWOT ANALYSIS
8.3.4. STRATEGIC ANALYSIS
8.4. BAYER A
8.4.1. COMPANY OVERVIEW
8.4.2. PRODUCT PORTFOLIO
8.4.3. SWOT ANALYSIS
8.4.4. STRATEGIC ANALYSIS
8.5. BOEHRINGER INGELHEIM
8.5.1. COMPANY OVERVIEW
8.5.2. PRODUCT PORTFOLIO
8.5.3. SWOT ANALYSIS
8.5.4. STRUCTURAL ANALYSIS
8.6. PFIZER, INC.
8.6.1. COMPANY OVERVIEW
8.6.2. SWOT ANALYSIS
8.6.3. STRATEGIC ANALYSIS
8.7. GLAXOSMITHKLINE LLC
8.7.1. COMPANY OVERVIEW
8.7.2. PRODUCT PORTFOLIO
8.7.3. SWOT ANALYSIS
8.7.4. STRATEGIC ANALYSIS
8.8. ELI LIL
8.8.1. COMPANY OVERVIEW
8.8.2. PRODUCT PORTFOLIO
8.8.3. SWOT ANALYSIS
8.8.4. STRATEGIC ANALYSIS
8.9. MERCK & CO. INC.
8.9.1. COMPANY OVERVIEW
8.9.2. PRODUCT PORTFOLIO
8.9.3. SWOT ANALYSIS
8.9.4. STRATEGIC ANALYSIS
8.10. ROCHE HOLDING AG
8.10.1. COMPANY OVERVIEW
8.10.2. PRODUCT PORTFOLIO
8.10.3. SWOT ANALYSIS
8.10.4. STRATEGIC ANALYSIS
TABLE LIST
TABLE 1 FACT SHEET OF EUROPE FATALITIES
TABLE 2 EUROPE QPCR MARKET, 2016-2024, (IN $MILLION)
TABLE 3 EUROPE DNA MICROARRAYS, 2016-2024, (IN $MILLION)
TABLE 4 EUROPE PROTEIN MICROARRAYS, 2016-2024(IN $MILLION)
TABLE 5 EUROPE HIGH THROUGHPUT SCREENING, 2016-2024(IN $MILLION)
TABLE 6 EUROPE MASS SPECTROMETRY, 2016-2024(IN $MILLION)
TABLE 7 EUROPE GEL ELECTROPHORESIS MARKET, 2016-2024, (IN $MILLION)
TABLE 8 EUROPE CHROMATOGRAPHY MARKET, 2016-2024 (IN $MILLION)
TABLE 9 EUROPE PROTEIN AND NUCLEIC ACID ISOLATION MARKET, 2016-2024 (IN $MILLION)
TABLE 10 EUROPE OTHER TECHNOLOGIES MARKET, 2016-2024 (IN $MILLION)
TABLE 11 EUROPE DRUG DISCOVERY MARKET, 2016-2024, (IN $MILLION)
TABLE 12 FATALITY IN EUROPE IN 2012
FIGURES LIST
FIGURE 1 EUROPE DRUG DISCOVERY MARKET, 2016-2024, (IN $MILLION)
FIGURE 2 EUROPE DRUG DISCOVERY MARKET SHARE, BY TECHNOLOGY, 2016 & 2024
FIGURE 3 EUROPE QPCR MARKET, 2016-2024 (IN $MILLION)
FIGURE 4 EUROPE DNA MICROARRAYS MARKET, 2016-2024 (IN $MILLION)
FIGURE 5 EUROPE PROTEIN MICROARRAYS MARKET, 2016-2024 (IN $MILLION)
FIGURE 6 EUROPE HIGH THROUGHPUT SCREENING MARKET, 2016-2024 (IN $MILLION)
FIGURE 7 EUROPE MASS SPECTROMETRY MARKET, 2016-2024 (IN $MILLION)
FIGURE 8 EUROPE GEL ELECTROPHORESIS MARKET, 2016-2024 (IN $MILLION)
FIGURE 9 EUROPE CHROMATOGRAPHY MARKET, 2016-2024 (IN $MILLION)
FIGURE 10 EUROPE PROTEIN AND NUCLEIC ACID ISOLATION MARKET, 2016-2024 (IN $MILLION)
FIGURE 11 EUROPE OTHER TECHNOLOGIES MARKET, 2016-2024 (IN $MILLION)
FIGURE 12 EUROPE DRUG DISCOVERY MARKET, 2016-2024, (IN $MILLION)
FIGURE 13 COUNTRY-WISE MARKET SHARE, 2016
FIGURE 14 UNITED KINGDOM DRUG DISCOVERY MARKET, 2016-2024, (IN $MILLION)
FIGURE 15 FRANCE DRUG DISCOVERY MARKET, 2016-2024, (IN $MILLION)
FIGURE 16 GERMAN DRUG DISCOVERY MARKET, 2016-2024 (IN $MILLION)
FIGURE 17 SPAIN DRUG DISCOVERY MARKET, 2016-2024, (IN $MILLION)
FIGURE 18 ITALY DRUG DISCOVERY MARKET, 2016-2024 (IN $MILLION)
FIGURE 19 REST OF EUROPE (ROE) DRUG DISCOVERY MARKET, 2016-2024 (IN $MILLION)
